Illumina Says 'Significant Growth' in Sequencing Demand Drove 12-Percent Rise in Q4 Revenue | GenomeWeb

By Julia Karow

This article, originally published Feb. 5, has been updated with additional information from Illumina's conference call.

Illumina last week reported that fourth-quarter revenue increased 12 percent — slightly higher than it projected a few weeks ago — largely resulting from continued growth in sales of its sequencing products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.